CNS Drugs

, Volume 32, Issue 10, pp 917–938 | Cite as

Antipsychotic-Associated Symptoms of Tourette Syndrome: A Systematic Review

  • David D. Kim
  • Alasdair M. Barr
  • Yunsun Chung
  • Jessica W. Y. Yuen
  • Mahyar Etminan
  • Bruce C. Carleton
  • Randall F. White
  • William G. Honer
  • Ric M. ProcyshynEmail author
Systematic Review



Although antipsychotics are used to treat Tourette syndrome, there have been reports of paradoxical induction of tics by first- and second-generation antipsychotics.


The objective of this systematic review was to better characterize tics as the potential adverse effect of antipsychotics.


A literature search was performed, with no language restriction, using the MEDLINE, EMBASE, and PsycINFO databases for all publications up to January 2018. To be included, studies utilizing any study design had to meet the following criteria: (1) a temporal association of tics with antipsychotic use where tics emerged during treatment or after discontinuation and (2) no diagnosis of Tourette syndrome before tic emergence. More stringent criteria were used for individuals under 18 years of age that included (1) no personal or family history of primary tic disorder and either (2) tics occurring during antipsychotic treatment improved significantly upon discontinuation or dose reduction or (3) tics emerged after discontinuation of at least 3 months of antipsychotic treatment. Data were extracted according to: age, sex, diagnosis, personal history of motor symptoms or family history of tics, antipsychotic type and dose, treatment duration, types of symptoms emerged, treatment strategies, and follow-up. A Fisher’s exact test was used to compare the occurrence of symptoms between first- and second-generation antipsychotic users.


The search identified 1290 articles, of which 92 full-text articles were assessed leading to the inclusion of 50 articles. Most of the included articles were case reports or series, involving a total of 60 cases. Thirty cases were associated with treatment with first-generation antipsychotics, 27 with second-generation antipsychotics, and three with a combination of first- and second-generation antipsychotics. Antipsychotics were being used to treat schizophrenia in 60% of the cases and other indications included developmental, behavioral, and mood or anxiety disorders. Tics occurred during treatment (n = 44) or following treatment discontinuation (n = 16). The occurrence of vocal tics with or without motor tics was significantly higher in the first- vs. second-generation antipsychotic users (p < 0.0001). Significantly higher occurrences were also noted in the first- vs. second-generation antipsychotic users for specific types of vocal tics (i.e., barking and coprolalia) and other concurrent motor symptoms (i.e., tardive dyskinesia). In the cases identified, antipsychotic-associated tics were treated by (1) discontinuing the offending antipsychotic, reducing its dose, or switching to different antipsychotics for tics occurring during treatment, (2) reinitiating antipsychotic treatment for tics occurring following discontinuation, or (3) using non-antipsychotic agents. It should be noted that symptoms were not always fully reversible and recurred at times.


Tics can be a disturbing adverse effect of antipsychotics. Clinicians need to be particularly vigilant when initiating and modifying antipsychotic regimens.


Compliance with Ethical Standards


No sources of funding were used to assist with the preparation of this article.

Conflict of interest

Alasdair M. Barr has received grants from Bristol-Myers Squibb and the Canadian Institutes of Health Research. Bruce C. Carleton is part of the Pharmaceutical Outcomes Programme and has received financial support for its pharmacoepidemiological research from the British Columbia Provincial Health Services Authority; he also serves on a data safety board for AEVI Genomic Medicine. Randall F. White has received consulting fees or sat on paid advisory boards for: Janssen, Lundbeck, and Otsuka; and has received a grant from ThermoFisher/Affymetrix. William G. Honer has received consulting fees or sat on paid advisory boards for: the Canadian Agency for Drugs and Technology in Health, the Centre for Drug Research and Development, AlphaSights, In Silico (unpaid), and Otsuka/Lundbeck. Ric M. Procyshyn has received consulting fees or sat on paid advisory boards for: Janssen, Lundbeck, and Otsuka; is on the speaker’s bureau for Janssen, Lundbeck, and Otsuka; and has received grants from the Canadian Institutes of Health Research. David D. Kim, Yunsun Chung, Jessica W.Y. Yuen, and Mahyar Etminan have no conflicts of interest directly relevant to the contents of this article.


  1. 1.
    Dayalu P, Chou KL. Antipsychotic-induced extrapyramidal symptoms and their management. Expert Opin Pharmacother. 2008;9:1451–62.CrossRefPubMedGoogle Scholar
  2. 2.
    Waln O, Jankovic J. An update on tardive dyskinesia: from phenomenology to treatment. Tremor Other Hyperkinet Mov (N Y). 2013. Scholar
  3. 3.
    Cohen SC, Leckman JF, Bloch MH. Clinical assessment of Tourette syndrome and tic disorders. Neurosci Biobehav Rev. 2013;37:997–1007.CrossRefPubMedGoogle Scholar
  4. 4.
    Wong DF, Brasić JR, Singer HS, Schretlen DJ, Kuwabara H, Zhou Y, Nandi A, Maris MA, Alexander M, Ye W, Rousset O, Kumar A, Szabo Z, Gjedde A, Grace AA. Mechanisms of dopaminergic and serotonergic neurotransmission in Tourette syndrome: clues from an in vivo neurochemistry study with PET. Neuropsychopharmacology. 2008;33:1239–51.CrossRefPubMedGoogle Scholar
  5. 5.
    Denys D, de Vries F, Cath D, Figee M, Vulink N, Veltman DJ, van der Doef TF, Boellaard R, Westenberg H, van Balkom A, Lammertsma AA, van Berckel BN. Dopaminergic activity in Tourette syndrome and obsessive-compulsive disorder. Eur Neuropsychopharmacol. 2013;23:1423–31.CrossRefPubMedGoogle Scholar
  6. 6.
    Weisman H, Qureshi IA, Leckman JF, Scahill L, Bloch MH. Systematic review: pharmacological treatment of tic disorders: efficacy of antipsychotic and alpha-2 adrenergic agonist agents. Neurosci Biobehav Rev. 2013;37:1162–71.CrossRefPubMedGoogle Scholar
  7. 7.
    Klawans HL, Falk DK, Nausieda PA, Weiner WJ. Gilles de la Tourette syndrome after long-term chlorpromazine therapy. Neurology. 1978;28:1064–6.CrossRefPubMedGoogle Scholar
  8. 8.
    Stahl SM. Tardive Tourette syndrome in an autistic patient after long-term neuroleptic administration. Am J Psychiatry. 1980;137:1267–9.CrossRefPubMedGoogle Scholar
  9. 9.
    Fountoulakis KN, Samara M, Siapera M, Iacovides A. Tardive Tourette-like syndrome: a systematic review. Int Clin Psychopharmacol. 2011;26:237–42.CrossRefPubMedGoogle Scholar
  10. 10.
    Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry. 1982;39:486–7.PubMedGoogle Scholar
  12. 12.
    Doepp S, Buddeberg C. Extrapyramidal symptoms following clozapine therapy: case report. Nervenarzt. 1975;46:589–90.PubMedGoogle Scholar
  13. 13.
    Pary RJ. The “psychotic” curse. Am J Psychiatry. 1979;136:715–6.CrossRefPubMedGoogle Scholar
  14. 14.
    DeVeaugh-Geiss J. Tardive Tourette syndrome. Neurology. 1980;30:562–3.CrossRefPubMedGoogle Scholar
  15. 15.
    Seeman MV, Patel J, Pyke J. Tardive dyskinesia with Tourette-like syndrome. J Clin Psychiatry. 1981;42:357–8.PubMedGoogle Scholar
  16. 16.
    Singer WD. Transient Gilles de la Tourette syndrome after chronic neuroleptic withdrawal. Dev Med Child Neurol. 1981;23:518–21.CrossRefPubMedGoogle Scholar
  17. 17.
    Fog R, Pakkenberg H, Regeur L, Pakkenberg B. “Tardive” Tourette syndrome in relation to long-term neuroleptic treatment of multiple tics. Adv Neurol. 1982;35:419–21.PubMedGoogle Scholar
  18. 18.
    Klawans HL, Nausieda PA, Goetz CC, Tanner CM, Weiner WJ. Tourette-like symptoms following chronic neuroleptic therapy. Adv Neurol. 1982;35:415–8.PubMedGoogle Scholar
  19. 19.
    Mueller J, Aminoff MJ. Tourette-like syndrome after long-term neuroleptic drug treatment. Br J Psychiatry. 1982;141:191–3.CrossRefPubMedGoogle Scholar
  20. 20.
    Jeste DV, Cutler NR, Kaufmann CA, Karoum F. Low-dose apomorphine and bromocriptine in neuroleptic-induced movement disorders. Biol Psychiatry. 1983;18:1085–91.PubMedGoogle Scholar
  21. 21.
    Munetz MR, Slawsky RC, Neil JF. Tardive Tourette’s syndrome treated with clonidine and mesoridazine. Psychosomatics. 1985;26(254):257.Google Scholar
  22. 22.
    Gualtieri CT, Patterson DR. Neuroleptic-induced tics in two hyperactive children. Am J Psychiatry. 1986;143:1176–7.CrossRefPubMedGoogle Scholar
  23. 23.
    Lal S, AlAnsari E. Tourette-like syndrome following low dose short-term neuroleptic treatment. Can J Neurol Sci. 1986;13:125–8.CrossRefPubMedGoogle Scholar
  24. 24.
    Perry R, Nobler MS, Campbell M. Tourette-like symptoms associated with neuroleptic therapy in an autistic child. J Am Acad Child Adolesc Psychiatry. 1989;28:93–6.CrossRefPubMedGoogle Scholar
  25. 25.
    Karagianis JL, Nagpurkar R. A case of Tourette syndrome developing during haloperidol treatment. Can J Psychiatry. 1990;35:228–32.CrossRefPubMedGoogle Scholar
  26. 26.
    Littlejohns CS, Clarke DJ, Corbett JA. Tourette-like disorder in Asperger’s syndrome. Br J Psychiatry. 1990;156:430–3.CrossRefPubMedGoogle Scholar
  27. 27.
    Diaz JM, Smith KG, Maccario M. Exacerbation of motor tic and induction of new tic by haloperidol use. West J Med. 1992;156:198–9.PubMedPubMedCentralGoogle Scholar
  28. 28.
    Kuniyoshi M, Inanaga K, Arikawa K, Maeda Y, Nakamura J, Uchimura N. A case of tardive Tourette-like syndrome. Jpn J Psychiatry Neurol. 1992;46:67–70.PubMedGoogle Scholar
  29. 29.
    Bharucha KJ, Sethi KD. Tardive tourettism after exposure to neuroleptic therapy. Mov Disord. 1995;10:791–3.CrossRefPubMedGoogle Scholar
  30. 30.
    Jaffe E, Trémeau F, Sharif Z, Reider R. Clozapine in tardive Tourette syndrome. Biol Psychiatry. 1995;38:196–7.CrossRefPubMedGoogle Scholar
  31. 31.
    Lindenmayer JP, Da Silva D, Buendia A, Zylberman I, Vital-Herne M. Tic-like syndrome after treatment with clozapine. Am J Psychiatry. 1995;152:649.CrossRefPubMedGoogle Scholar
  32. 32.
    Myers B, Pueschel SM. Tardive or atypical Tourette’s disorder in a population with Down syndrome? Res Dev Disabil. 1995;16:1–9.CrossRefPubMedGoogle Scholar
  33. 33.
    Brasić JR, Barnett JY, Aisemberg P, Ahn SC, Nadrich RH, Kaplan D, Ahmad R, Mendonça Mde F. Dyskinesias subside off all medication in a boy with autistic disorder and severe mental retardation. Psychol Rep. 1997;81:755–67.CrossRefPubMedGoogle Scholar
  34. 34.
    Landry P, Cournoyer J. Acute dystonia with olanzapine. J Clin Psychiatry. 1998;59:384.CrossRefPubMedGoogle Scholar
  35. 35.
    Poyurovsky M, Bergman Y, Shoshani D, Schneidman M, Weizman A. Emergence of obsessive-compulsive symptoms and tics during clozapine withdrawal. Clin Neuropharmacol. 1998;21:97–100.PubMedGoogle Scholar
  36. 36.
    Huang SC, Lai TJ, Tsai SJ. A case report of quetiapine-related tic-like symptoms. J Clin Psychiatry. 2002;63:1184–5.CrossRefPubMedGoogle Scholar
  37. 37.
    Reid SD. Neuroleptic-induced tardive Tourette treated with clonazepam: a case report and literature review. Clin Neuropharmacol. 2004;27:101–4.CrossRefPubMedGoogle Scholar
  38. 38.
    Begum M. Clozapine-induced stuttering, facial tics and myoclonic seizures: a case report. Aust N Z J Psychiatry. 2005;39:202.CrossRefPubMedGoogle Scholar
  39. 39.
    Alonso-Navarro H, Jiménez-Jiménez FJ. Amisulpride-induced tardive motor and phonic tics. Clin Neuropharmacol. 2006;29:163–4.CrossRefPubMedGoogle Scholar
  40. 40.
    Feroz-Nainar C, Roy M. Risperidone and late onset tics. Autism. 2006;10:302–7.CrossRefPubMedGoogle Scholar
  41. 41.
    Lin CL, Shiah IS, Yeh CB, Wan FJ, Wang TS. Amisulpride related tic-like symptoms in an adolescent schizophrenic. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30:144–6.CrossRefPubMedGoogle Scholar
  42. 42.
    Yamauchi K, Ohmori T. Two cases of tardive Tourette syndrome. Seishin Shinkeigaku Zasshi. 2006;108:459–65.PubMedGoogle Scholar
  43. 43.
    Cheng WJ, Liu HC, Huang MC. Olanzapine monotherapy for late-onset vocal tics in a schizophrenic patient. Psychiatry Clin Neurosci. 2007;61:700–1.CrossRefPubMedGoogle Scholar
  44. 44.
    Hallahan B, Murray I, Doyle PG. Clozapine induced stuttering. Ir J Psych Med. 2007;24:121.CrossRefGoogle Scholar
  45. 45.
    Kozian R, Friederich M. Gilles-de-la-Tourette syndrome as a tardive dyskinesia. Psychiatr Prax. 2007;34:253–4.CrossRefPubMedGoogle Scholar
  46. 46.
    Lyall M, Pryor A, Murray K. Clozapine and speech dysfluency: two case reports. Psychiatr Bull. 2007;31:16–8.CrossRefGoogle Scholar
  47. 47.
    Bastiampillai T, Dhillon R, Mohindra R. Exacerbation of tics secondary to clozapine therapy. Aust N Z J Psychiatry. 2008;42:1068–70.PubMedGoogle Scholar
  48. 48.
    Su JA, Tsang HY, Chou SY, Chung PC. Aripiprazole treatment for risperidone-associated tic movement: a case report. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32:899–900.CrossRefPubMedGoogle Scholar
  49. 49.
    Willmund G, Lee AH, Wertenauer F, Laier SA, Lang UE. Vocal tics associated with ziprasidone. J Clin Psychopharmacol. 2009;29:611–2.CrossRefPubMedGoogle Scholar
  50. 50.
    Fountoulakis KN, Panagiotidis P. Tardive Tourette-like syndrome in a patient treated with paliperidone. J Neuropsychiatry Clin Neurosci. 2011;23:E35–6.CrossRefPubMedGoogle Scholar
  51. 51.
    Paparrigopoulos T, Persefonis G, Tzavellas E, Karaiskos D, Liappas I. Tourette syndrome (TS) mimicking tardive dystonia. Eur Psychiatry. 2011;26:980.CrossRefGoogle Scholar
  52. 52.
    Azevedo JC, Lopes R, Curral R, Esteves MF, Coelho R, Roma-Torres A. Clozapine-induced palilalia? Acta Neuropsychiatr. 2012;24:122–4.CrossRefPubMedGoogle Scholar
  53. 53.
    Yogaratnam J, Xu C, Thinn DS, Yoong LK, Khoo CL, Sim K. De novo tardive Tourette-like syndrome after prolonged combination depot and oral neuroleptic therapy. Acta Neuropsychiatr. 2013;25:122–4.CrossRefPubMedGoogle Scholar
  54. 54.
    Chen S, Gong H, Chen X. Quetiapine-related tic in a pediatric bipolar patient. J Child Adolesc Psychopharmacol. 2014;24:165.CrossRefPubMedGoogle Scholar
  55. 55.
    Hsieh MH, Chiu NY. Paliperidone-associated motor tics. Gen Hosp Psychiatry. 2014;36(360):e7–8.Google Scholar
  56. 56.
    Guo X, Lu D, Jiang Y. Aripiprazole-associated tic in a schizophrenia patient. Neuropsychiatr Dis Treat. 2015;11:873–4.PubMedPubMedCentralGoogle Scholar
  57. 57.
    Mazlum B, Zaimoğlu S, Öztop DB. Exacerbation of tics after combining aripiprazole with pimozide: a case with Tourette syndrome. J Clin Psychopharmacol. 2015;35:350–1.CrossRefPubMedGoogle Scholar
  58. 58.
    Akaltun İ, Kara T. Tic disorder developing following risperidone in a child with oppositional defiant disorder. Psychiatry Clin Psychopharmacol. 2018;28:113–5.CrossRefGoogle Scholar
  59. 59.
    Mills EW, Shaffer LS, Goes FS, Sawa A, Nucifora FC Jr. Case of secondary tics associated with olanzapine in an adult. Front Psychiatry. 2017;8:150.CrossRefPubMedPubMedCentralGoogle Scholar
  60. 60.
    US Department of Health and Human Services, National Institutes of Health, National Institute of Neurological Disorders and Stroke. 2012. NINDS Tourette syndrome fact sheet (NIH Publication No. 12-2163). Accessed 2 Aug 2018.
  61. 61.
    Yin J, Barr AM, Ramos-Miguel A, Procyshyn RM. Antipsychotic induced dopamine supersensitivity psychosis: a comprehensive review. Curr Neuropharmacol. 2017;15:174–83.CrossRefPubMedPubMedCentralGoogle Scholar
  62. 62.
    Horacek J, Bubenikova-Valesova V, Kopecek M, Palenicek T, Dockery C, Mohr P, Höschl C. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs. 2006;20:389–409.CrossRefPubMedGoogle Scholar
  63. 63.
    Seeman P. Targeting the dopamine D2 receptor in schizophrenia. Expert Opin Ther Targets. 2006;10:515–31.CrossRefPubMedGoogle Scholar
  64. 64.
    Caine ED, Polinsky RJ, Kartzinel R, Ebert MH. The trial use of clozapine for abnormal involuntary movement disorders. Am J Psychiatry. 1979;136:317–20.CrossRefPubMedGoogle Scholar
  65. 65.
    Schoemaker H, Claustre Y, Fage D, Rouquier L, Chergui K, Curet O, Oblin A, Gonon F, Carter C, Benavides J, Scatton B. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity. J Pharmacol Exp Ther. 1997;280:83–97.PubMedGoogle Scholar
  66. 66.
    Minzenberg MJ, Yoon JH. An index of relative central α-adrenergic receptor antagonism by antipsychotic medications. Exp Clin Psychopharmacol. 2011;19:31–9.CrossRefPubMedGoogle Scholar
  67. 67.
    Tanner CM, Goetz CG, Klawans HL. Cholinergic mechanisms in Tourette syndrome. Neurology. 1982;32:1315–7.CrossRefPubMedGoogle Scholar
  68. 68.
    Xu M, Kobets A, Du JC, Lennington J, Li L, Banasr M, Duman RS, Vaccarino FM, DiLeone RJ, Pittenger C. Targeted ablation of cholinergic interneurons in the dorsolateral striatum produces behavioral manifestations of Tourette syndrome. Proc Natl Acad Sci USA. 2015;112:893–8.CrossRefPubMedGoogle Scholar
  69. 69.
    Minzenberg MJ, Poole JH, Benton C, Vinogradov S. Association of anticholinergic load with impairment of complex attention and memory in schizophrenia. Am J Psychiatry. 2004;161:116–24.CrossRefPubMedGoogle Scholar
  70. 70.
    Schirmbeck F, Zink M. Clozapine-induced obsessive-compulsive symptoms in schizophrenia: a critical review. Curr Neuropharmacol. 2012;10:88–95.CrossRefPubMedPubMedCentralGoogle Scholar
  71. 71.
    Mulligan HF, Anderson TJ, Jones RD, Williams MJ, Donaldson IM. Tics and developmental stuttering. Parkinsonism Relat Disord. 2003;9:281–9.CrossRefPubMedGoogle Scholar
  72. 72.
    Watkins KE, Smith SM, Davis S, Howell P. Structural and functional abnormalities of the motor system in developmental stuttering. Brain. 2008;131:50–9.CrossRefPubMedGoogle Scholar
  73. 73.
    Nath K, Bhattacharya A, Hazarika S, Roy D, Praharaj SK. Paradoxical worsening of tics with haloperidol. Ther Adv Psychopharmacol. 2015;5:314–5.CrossRefPubMedPubMedCentralGoogle Scholar
  74. 74.
    Lan CC, Liu CC, Chen YS. Quetiapine and clozapine combination treatment for Tourette’s syndrome in an adolescent boy: potential role of dopamine supersensitivity in loss of treatment response. J Child Adolesc Psychopharmacol. 2015;25:188–90.CrossRefPubMedGoogle Scholar
  75. 75.
    Robakis D. How much do we know about adult-onset primary tics? Prevalence, epidemiology, and clinical features. Tremor Other Hyperkinet Mov (N Y). 2017;7:441.PubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  • David D. Kim
    • 1
  • Alasdair M. Barr
    • 1
  • Yunsun Chung
    • 2
  • Jessica W. Y. Yuen
    • 3
  • Mahyar Etminan
    • 4
  • Bruce C. Carleton
    • 2
    • 5
    • 6
  • Randall F. White
    • 7
  • William G. Honer
    • 7
  • Ric M. Procyshyn
    • 7
    Email author
  1. 1.Department of Anesthesiology, Pharmacology and TherapeuticsUniversity of British ColumbiaVancouverCanada
  2. 2.British Columbia Children’s Hospital Research InstituteVancouverCanada
  3. 3.Faculty of Medicine and Centre for Brain HealthUniversity of British ColumbiaVancouverCanada
  4. 4.Department of Ophthalmology and Visual SciencesUniversity of British ColumbiaVancouverCanada
  5. 5.Division of Translational Therapeutics, Department of PediatricsUniversity of British ColumbiaVancouverCanada
  6. 6.Pharmaceutical Outcomes ProgrammeBritish Columbia Children’s HospitalVancouverCanada
  7. 7.Department of PsychiatryUniversity of British ColumbiaVancouverCanada

Personalised recommendations